Tag Archives: tenofovir alafenamide

October, 2018

30 October
Janssen Presents Positive Long-Term Efficacy and Safety of Symtuza in Treatment-Naïve Adults with HIV-1

GLASGOW, Scotland–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF)) at HIV Glasgow in Scotland. D/C/F/TAF is a once-daily darunavir-based single-tablet regimen (STR), …
Share
30 October
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy for Treatment of HIV-1 in Treatment-Naïve Adults

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing study, …
Share

21 January
Strides Enters Licensing Deal with Gilead for HIV Drug

Indian generic drugmaker Strides Arcolab recently announced that it has entered a licensing deal to distribute Gilead Sciences’ HIV drug. The company said that it has entered into a licensing agreement with Gilead, under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both …
Share